Heart failure & cardiomyopathies
Repetitive Levosimendan Infusions for Patients with Advanced Chronic Heart Failure in the Vulnerable Post-Discharge Period: The Multinational Randomized LeoDOR Trial
Authors' conclusion
Among patients recently hospitalized with HF and reduced LVEF, intermittent levosimendan therapy did not improve post-hospitalization clinical stability.
Study context
- Population
- Patients with advanced heart failure (HF) and left ventricular ejection fraction (LVEF) ≤30%, at the end of an index hospitalisation for acute HFmodified ITT
- Participants
- 145 patients
- Comparison
- Intermittent levosimendan vs placebo
- Levosimendann = 93
- Placebon = 52reference
Methodological detailsmulticentre, double-blind, placebo-controlled, 2:1 randomisation, multinational
- Multicentre
- Double-blind
- Placebo-controlled
- 2:1 randomisation
- Multinational
Primary result
As reported in the abstract
Mean rank score · 14 weeks
Levosimendan
72.55
mean rank score
Placebo
73.81
mean rank score
P = 0.863
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Individual clinical components of the primary endpoint · 14 weeks | 2.94 (1.12–7.68) | P = 0.021 | |
| Individual clinical components of the primary endpoint · 26 weeks | 1.64 (0.87–3.11) | P = 0.122 | |
| 0.10.31310Hazard ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Repetitive Levosimendan Infusions for Patients with Advanced Chronic Heart Failure in the Vulnerable Post-Discharge Period: The Multinational Randomized LeoDOR Trial. Eur J Heart Fail. Published 4 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →